COMBINACIÓN DE UN AGENTE QUIMIOTERAPÉUTICO Y UN INHIBIDOR DEL SISTEMA TGF-BETA

• Main Authors: ROTHAMMER, TANJA, JASCHINSKI, FRANK, SCHNEIDER, ANNELIESE, SCHLINGENSIEPEN, KARL HERMANN
• Format: Patent
• Language: Spanish
• Published: 29.06.2012
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPIRITS; VINEGAR; WINE

Composición farmacéutica que comprende un agente quimioterapéutico y un oligonucleótido antisentido contra TGF-beta, donde el oligonucleótido antisentido reduce la sensibilidad y la IC50, respectivamente, de la citotoxicidad del agente quimioterapéutico. De preferencia, el oligonucleótido antisentido es un oligonucleótido antisentido contra TGF-beta 1, 2 y/o 3 y el agente quimioterapéutico de preferencia es gemcitabina, 5-fluorouracilo, temozolomida, dacarbacina, docetaxel, cisplatino, oxaliplatino, tamoxifeno o irinotecán. Pharmaceutical composition comprising a chemotherapeutic agent and a TGF-beta antisense oligonucleotide, wherein the antisense oligonucleotide reduces the sensitivity and IC50, respectively, of the cytotoxicity of the chemotherapeutic agent. Preferably, the antisense oligonucleotide is a TGF-beta 1, 2, and/or 3 antisense oligonucleotide and the chemotherapeutic agent is preferably gemcitabine, 5-fluorouracil, temozolomide, dacarbacine, docetaxel, cisplatin, oxaliplatin, tamoxifen, or irinotecan.